Feed Preview

Fast Growing


Immunosuppression diagram by Marilia Normanton et al
Marilia Normanton et al

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Top 20 most recent papers

Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients

CellsDecember 5, 2019
Halvard B BonigPeter Bader
Journal of Autoimmunity

Evolving story of autoantibodies in systemic lupus erythematosus

Journal of AutoimmunityDecember 3, 2019
David S Pisetsky
Cancer Medicine

Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma

Cancer MedicineDecember 10, 2019
Tareq M AnssarCorinna Seliger

The Role of Vitamin D and Omega-3 PUFAs in Islet Transplantation

NutrientsDecember 3, 2019
Marco InfanteRodolfo Alejandro
Clinical Pharmacokinetics

Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation

Clinical PharmacokineticsDecember 10, 2019
Maaike A SikmaErik M van Maarseveen
Pediatric Transplantation

Assessment of rejection risk following subtherapeutic calcineurin inhibitor levels after pediatric heart transplantation

Pediatric TransplantationDecember 10, 2019
Sarah M KerrMariska S Kemna
Clinical Rheumatology

A quality improvement intervention failed to significantly increase pneumococcal and influenza vaccination rates in immunosuppressed inflammatory arthritis patients

Clinical RheumatologyDecember 9, 2019
Kieran E MurrayDouglas James Veale

ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output

CancersDecember 6, 2019
Erika TerzuoliMarina Ziche
Cell Death & Disease

Cancer-educated mesenchymal stem cells promote the survival of cancer cells at primary and distant metastatic sites via the expansion of bone marrow-derived-PMN-MDSCs

Cell Death & DiseaseDecember 9, 2019
Buqing SaiJuan-juan Xiang
Cancer Immunology, Immunotherapy : CII

Mechanisms of immune evasion in bladder cancer

Cancer Immunology, Immunotherapy : CIIDecember 6, 2019
Paul L Crispen, Sergei A Kusmartsev
Journal of Psychiatric Practice

Catatonia Due to Tacrolimus Toxicity 16 Years After Renal Transplantation: Case Report and Literature Review

Journal of Psychiatric PracticeNovember 1, 2019
Daniel SikaviJohn A Fromson
Therapeutics and Clinical Risk Management

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study

Therapeutics and Clinical Risk ManagementDecember 2, 2019
Antoni Sicras-MainarJosé Carlos Armario-Hita
Handbook of Experimental Pharmacology

Immunosuppressants in Organ Transplantation

Handbook of Experimental PharmacologyDecember 10, 2019
Burkhard Tönshoff
British Journal of Cancer

Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma

British Journal of CancerDecember 10, 2019
Gang MengJi-Wu Wei
International Journal of Molecular Sciences

Development of a Highly Efficient Hybrid Peptide That Increases Immunomodulatory Activity Via the TLR4-Mediated Nuclear Factor-κB Signaling Pathway

International Journal of Molecular SciencesDecember 6, 2019
Lu-lu ZhangJun-Yong Wang
ClinicoEconomics and Outcomes Research : CEOR

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States

ClinicoEconomics and Outcomes Research : CEORNovember 12, 2019
Gabriel TremblayAnna Forsythe
Critical Care : the Official Journal of the Critical Care Forum

Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI)

Critical Care : the Official Journal of the Critical Care ForumDecember 9, 2019
Carolin F MantheyValentin Fuhrmann
International Urology and Nephrology

Association of diabetes with failure to achieve complete remission of idiopathic membranous nephropathy

International Urology and NephrologyDecember 9, 2019
Huai-Ya XieXue-wang Li
Clinical and Experimental Rheumatology

Segmental arterial mediolysis: a vasculitis mimiker. A single centre experience

Clinical and Experimental RheumatologyDecember 9, 2019
Marwan Abu SneinehGabriel S Breuer
International Journal of Nanomedicine

The In Vitro Immunomodulatory Effects Of Gold Nanoparticles Synthesized From Hypoxis hemerocallidea Aqueous Extract And Hypoxoside On Macrophage And Natural Killer Cells

International Journal of NanomedicineNovember 19, 2019
Abdulrahman M ElbagoryMervin Meyer

See more papers from this feed

Related Feeds

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Exosomes & Tumor Environment

Several studies have reported the role of exosomes as important mediators of angiogenesis, metastasis, and immune modulation. Exosomes also have the potential to be used as biomarkers for clinical predictions. Here is the latest research on exosomes and the tumor microenvironment.

Graft Rejection

Graft rejection occurs when the donor's grafted tissue is rejected by the recipient's immune system, destroying the transplanted tissue. Discover the latest research on graft rejection here.

Graft vs Host Disease

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Here is the latest research.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.


Immuno-oncology (or cancer immunotherapy) is the artificial stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight cancer. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules. Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill. Discover the latest research on immuno-oncology here.

Metastatic Malignancy Treatments

Treatment of metastatic cancers depends on the type of cancer and the severity of the disease. The regime often includes medications such as chemotherapy or hormone therapy, but may also include immunotherapy, radiation therapy, surgery or a combination. Discover the latest research on metastatic cancer treatments here.

Tumor Evasion of the Immune System

Tumor evasion of the immune system includes cells that operate their own growth and develop various strategies to escape from immune surveillance. Discover the latest research on tumor evasion of the immune system here.

Tumor Vaccines

Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. Discover the latest research on tumor vaccines here.

© 2019 Meta ULC. All rights reserved